NECTAR-HF trial primary end point results reported by Boston Scientific .The trial evaluated 96 NHA (Newyork Heart Association) class 2-3 patients with heart failure.They are randomized in 2:1 ratio to treatment or sham.
However, the trial failed to meet pre specified 6 month primary efficacy endpoint of reduction in left ventricular end systolic diameter.
Although patients who received them felt better as assessed by quality of life questionnaire ,application of VNS failed to reveal clear benefits when compared to sham.
However, the trial failed to meet pre specified 6 month primary efficacy endpoint of reduction in left ventricular end systolic diameter.
Although patients who received them felt better as assessed by quality of life questionnaire ,application of VNS failed to reveal clear benefits when compared to sham.